Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects

Hanauer, 2002, ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial, Lancet, 59, 1541, 10.1016/S0140-6736(02)08512-4 Colombel, 2007, Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial, Gastroenterology, 132, 52, 10.1053/j.gastro.2006.11.041 Schreiber, 2007, Maintenance therapy with certolizumab pegol for Crohn's disease, N Engl J Med, 357, 239, 10.1056/NEJMoa062897 Present, 1999, Infliximab for the treatment of fistulas in patients with Crohn's disease, N Engl J Med, 340, 1398, 10.1056/NEJM199905063401804 Lichtenstein, 2005, Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease, Gastroenterology, 128, 862, 10.1053/j.gastro.2005.01.048 Feagan, 2008, A randomized trial of methotrexate in combination with infliximab for the treatment of Crohn's disease, Gut, 57, A66 Sandborn, 2007, Certolizumab pegol for the treatment of Crohn's disease, N Engl J Med, 357, 228, 10.1056/NEJMoa067594 Targan, 1997, A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group, N Engl J Med, 337, 1029, 10.1056/NEJM199710093371502 Hanauer, 2006, Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial, Gastroenterology, 130, 323, 10.1053/j.gastro.2005.11.030 Rutgeerts, 2006, Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease, Gastrointest Endosc, 63, 433, 10.1016/j.gie.2005.08.011 Lémann, 2006, Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial, Gastroenterology, 130, 1054, 10.1053/j.gastro.2006.02.014 Colombel, 2008, A randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy, Gut, 57, A1 Schnitzler, 2009, Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort, Gut, 58, 492, 10.1136/gut.2008.155812 Marting, 2007, Long term safety and efficacy of infliximab in routine practice, Acta Gastroenterol Belg, 10, D45 González-Lama, 2008, Open-label infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of response, Gastroenterol Hepatol, 31, 421, 10.1157/13125587 Vermeire, 2002, Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease, Am J Gastroenterol, 97, 2357, 10.1111/j.1572-0241.2002.05991.x Sands, 2004, Infliximab maintenance therapy for fistulizing Crohn's disease, N Engl J Med, 350, 876, 10.1056/NEJMoa030815 Van Assche, 2003, Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease, Am J Gastroenterol, 98, 332, 10.1016/S0002-9270(02)05909-9 Hyder, 2006, Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment, Dis Colon Rectum, 49, 1837, 10.1007/s10350-006-0656-5 Topstad, 2003, Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn's disease: a single center experience, Dis Colon Rectum, 46, 577, 10.1007/s10350-004-6611-4 Rutgeerts, 2005, Infliximab for induction and maintenance therapy for ulcerative colitis, N Engl J Med, 353, 2462, 10.1056/NEJMoa050516 Rutgeerts, 1999, Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease, Gastroenterology, 117, 761, 10.1016/S0016-5085(99)70332-X Regueiro, 2007, Infliximab dose intensification in Crohn's disease, Inflamm Bowel Dis, 13, 1093, 10.1002/ibd.20177 Gisbert, 2009, Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review, Am J Gastroenterol, 104, 760, 10.1038/ajg.2008.88 Sandborn, 2007, Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II Trial, Gut, 56, 1232, 10.1136/gut.2006.106781 Maini, 1998, Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis, Arthritis Rheum, 41, 1552, 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W Mortimore, 2001, Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor-alpha, in the treatment of Crohn's disease: is its efficacy augmented by steroid-sparing immunosuppressive therapy? The Infliximab User Group, Intern Med J, 31, 146, 10.1046/j.1445-5994.2001.00039.x Farrell, 2003, Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial, Gastroenterology, 124, 917, 10.1053/gast.2003.50145 Baert, 2003, Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease, N Engl J Med, 348, 601, 10.1056/NEJMoa020888 Hanauer, 2004, Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease, Clin Gastroenterol Hepatol, 2, 542, 10.1016/S1542-3565(04)00238-1 Rutgeerts, 2004, Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease, Gastroenterology, 126, 402, 10.1053/j.gastro.2003.11.014 Zabana, 2008, Infliximab reintroduction in patients with inflammatory bowel disease previously treated with a 3-infusion induction regimen is not associated to a higher rate of immune mediated adverse effects, J Crohn's Colitis, 2 Nestorov, 2005, Clinical pharmacokinetics of TNF antagonists: how do they differ?, Semin Arthritis Rheumatol, 34, 12, 10.1016/j.semarthrit.2005.01.004 Hwang, 2005, Immunogenicity of engineered antibodies, Methods, 36, 3, 10.1016/j.ymeth.2005.01.001 Maser, 2006, Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease, Clin Gastroenterol Hepatol, 4, 1248, 10.1016/j.cgh.2006.06.025 Sands, 2004, Infliximab maintenance therapy for fistulizing Crohn's disease, N Engl J Med, 350, 876, 10.1056/NEJMoa030815 St Clair, 2002, The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial, Arthritis Rheum, 46, 1451, 10.1002/art.10302 Van Assche, 2008, Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial, Gastroenterology, 134, 1861, 10.1053/j.gastro.2008.03.004 Karmiris, 2009, Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease, Gastroenterology, 137, 1628, 10.1053/j.gastro.2009.07.062 Bartelds, 2007, Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis, Ann Rheum Dis, 66, 921, 10.1136/ard.2006.065615 Sandborn, 2007, Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial, Ann Intern Med, 146, 829, 10.7326/0003-4819-146-12-200706190-00159 Vermeire, 2008, Efficacy and safety of Certolizumab Pegol in patients with active Crohn's disease who previously lost response or were intolerant to infliximab: open-label induction preliminary results of the welcome study, Gastroenterology, 134, A67, 10.1016/S0016-5085(08)60318-2 Allez, 2010, The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies, Aliment Pharmacol Ther, 31, 92, 10.1111/j.1365-2036.2009.04130.x Tracey, 2008, Tumor necrosis factor antagonists mechanisms of action: a comprehensive review, Pharmacol Therapeut, 117, 224, 10.1016/j.pharmthera.2007.10.001 Vermeire, 2007, Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease, Gut, 56, 1226, 10.1136/gut.2006.099978 Svenson, 2007, Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies, Rheumatology, 46, 1828, 10.1093/rheumatology/kem261 Candon, 2006, Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease, Clin Immunol, 118, 11, 10.1016/j.clim.2005.07.010 Ainsworth, 2008, Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease, Am J Gastroenterol, 103, 944, 10.1111/j.1572-0241.2007.01638.x Bendtzen, 2009, Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies, Scand J Gastroenterol, 13, 1 Bendtzen, 2006, Individualized monitoring of drug bioavailability and immunogenecity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab, Arthritis Rheum, 54, 3782, 10.1002/art.22214 Wolbink, 2006, Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis, Arthritis Rheum, 54, 711, 10.1002/art.21671 Van de Putte, 2004, Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed, Ann Rheum Dis, 63, 508, 10.1136/ard.2003.013052 Radstake, 2008, Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis, Ann Rheum Dis, 68, 1739, 10.1136/ard.2008.092833 Hanauer, 2004, Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease, Clin Gastroenterol Hepatol, 2, 542, 10.1016/S1542-3565(04)00238-1 Bennett, 2005, Adalimumab-induced asthma, Rheumatology, 44, 1199, 10.1093/rheumatology/keh676 Aarden, 2008, Immunogenicity of anti-tumor necrosis factor antibodies—toward improved methods of anti-antibody measurement, Curr Opin Immunol, 20, 431, 10.1016/j.coi.2008.06.011 Weinblatt, 2003, Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial, Arthritis Rheum, 48, 35, 10.1002/art.10697 Bender, 2007, Immunogenicity, efficacy and adverse events of adalimumab in RA patients, Rheumatol Int, 27, 269, 10.1007/s00296-006-0183-7 West, 2008, Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease, Aliment Pharmacol Ther, 28, 1122, 10.1111/j.1365-2036.2008.03828.x Tabrizi, 2006, Elimination mechanisms of therapeutic monoclonal antibodies, Drug Discov Today, 11, 81, 10.1016/S1359-6446(05)03638-X Wang, 2008, Monoclonal antibody pharmacokinetics and pharmacodynamics, Clin Pharmacol Ther, 84, 548, 10.1038/clpt.2008.170 Brambell, 1966, The transmission of immunity from mother to young and the catabolism of immunoglobulins, Lancet, 2, 1087, 10.1016/S0140-6736(66)92190-8 Ghetie, 1996, Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice, Eur J Immunol, 26, 690, 10.1002/eji.1830260327 Ghetie, 1997, FcRn: the MHC class I-related receptor that is more than an IgG transporter, Immunol Today, 18, 592, 10.1016/S0167-5699(97)01172-9 Raghavan, 1995, Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants, Biochemistry, 34, 14,649, 10.1021/bi00045a005 Dall'Acqua, 2002, Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences, J Immunol, 169, 5171, 10.4049/jimmunol.169.9.5171 Hinton, 2006, An engineered human IgG1 antibody with longer serum half-life, J Immunol, 176, 346, 10.4049/jimmunol.176.1.346 Ober, 2001, Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies, Int Immunol, 13, 1551, 10.1093/intimm/13.12.1551 Indik, 1995, The molecular dissection of Fc gamma receptor mediated phagocytosis, Blood, 86, 4389, 10.1182/blood.V86.12.4389.bloodjournal86124389 Kumpel, 2003, Clearance of red cells by monoclonal IgG3 anti-D in vivo is affected by the VF polymorphism of Fcgamma RIIIa (CD16), Clin Exp Immunol, 132, 81, 10.1046/j.1365-2249.2003.02119.x Maini, 1998, Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis, Arthritis Rheum, 41, 1552, 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W Bunescu, 2004, Enhanced Fcgamma receptor I, alphaMbeta2 integrin receptor expression by monocytes and neutrophils in rheumatoid arthritis: interaction with platelets, J Rheumatol, 31, 2347